Dyne Therapeutics (NASDAQ:DYN – Get Free Report) was downgraded by research analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a research note issued on Wednesday, MarketBeat reports. They presently have a $15.00 price objective on the stock, down from their previous price objective of $40.00. Oppenheimer‘s target price would indicate a potential downside of 11.97% from the company’s previous close.
A number of other analysts have also recently commented on DYN. Royal Bank Of Canada dropped their price target on shares of Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, September 9th. Robert W. Baird reduced their price objective on shares of Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research note on Wednesday, September 9th. Chardan Capital reissued a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a report on Wednesday, September 30th. HC Wainwright lowered their target price on shares of Dyne Therapeutics from $50.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, September 30th. Finally, Piper Sandler restated an “overweight” rating and set a $47.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $31.29.
Get Our Latest Stock Analysis on Dyne Therapeutics
Dyne Therapeutics Trading Up 0.4%
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, research analysts forecast that Dyne Therapeutics will post -3.59 EPS for the current year.
Insider Activity
In related news, Director Jason P. Rhodes sold 2,160,516 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the transaction, the director owned 428,946 shares of the company’s stock, valued at approximately $10,723,650. The trade was a 83.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian S. Posner bought 2,500 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $40,000.00. Following the acquisition, the director directly owned 27,000 shares in the company, valued at $432,000. This trade represents a 10.20% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders sold 2,598,706 shares of company stock valued at $65,432,671. Corporate insiders own 9.46% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Dyne Therapeutics during the 2nd quarter valued at about $275,500,000. Jupiter Topco LLC bought a new position in shares of Dyne Therapeutics in the second quarter worth approximately $266,634,000. Perceptive Advisors LLC increased its position in shares of Dyne Therapeutics by 34.2% in the first quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock worth $84,646,000 after purchasing an additional 1,189,895 shares during the last quarter. Orbimed Advisors LLC increased its position in shares of Dyne Therapeutics by 32.5% in the first quarter. Orbimed Advisors LLC now owns 2,917,884 shares of the company’s stock worth $52,901,000 after purchasing an additional 715,700 shares during the last quarter. Finally, Bank of America Corp DE bought a new stake in Dyne Therapeutics during the second quarter valued at approximately $49,604,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.
About Dyne Therapeutics
Dyne Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company’s research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge.
Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue.
Dyne’s pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.
Further Reading
- Five stocks we like better than Dyne Therapeutics
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
